Quote · The Peter Attia Drive
#403 ‒ Peptides: separating scientific promise from marketing hype
Where this was said
What peptides are and why they must be evaluated individually
At 3:45 · chapter starts 3:15
Nick prompts Peter with the most basic question — what even is a peptide? — and Peter uses it as a launchpad for a deeper epistemic point. A peptide is simply a short chain of amino acids; insulin is a peptide, and so are GLP-1 agonists, which have transformed medicine. But so are dozens of gray-market compounds with essentially no credible evidence behind them. The word 'peptide' conveys a naturalistic connotation — safe and effective by default — but Peter argues this is one of the greatest marketing sleights of hand of the past decade. Most of what's sold is synthetic, often deliberately modified to bind receptors more tightly or last longer than the natural molecule ever could. [1] — Peter Attia "Calling something a peptide is like calling something a drug — it's a chemical description, not a quality stamp. Insulin and GLP-1 agonists…" 03:42 The right approach isn't to evaluate 'peptides' but to evaluate specific peptides using specific questions.
Calling something a peptide is like calling something a drug — it's a chemical description, not a quality stamp. Insulin and GLP-1 agonists are peptides; so are dozens of compounds with zero credible evidence. The biggest marketing win of the last decade has been conflating the two.
